HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety profile, tolerability, pharmacokinetics
(PK), pharmacodynamics (PD), of oral vorinostat in combination with oral capecitabine given
on days 1-7 and 15-21 of a 28 day cycle in patients with advanced breast cancer, using RECIST
criteria.
This study was originally intended to be a phase 1/phase 2. The protocol was amended to make
this study a phase 1 only.